Genetic Signatures (GSS) H1 2025 earnings summary

Executive summary

• Sales increased 136% year-over-year to $8.5 million in 1H FY25, driven by strong respiratory demand in Australia and progress in the UK, with US market entry marked by the first commercial contract and FDA clearance for the GI parasite panel.

• Gross margin improved to 59% from 42% year-over-year, reflecting better inventory management.

• Statutory loss widened to $15.2 million, including a $6.8 million impairment from ceasing internal Next Generation instrument development and a strategic technology shift.

• Cash and cash equivalents stood at $40.8 million as of 31 December 2024, with no debt.

• Leadership changes included the appointment of Allison Rossiter as CEO and completion of Board renewal.

Financial highlights

• Revenue for 1H FY25 was $8.5 million, up from $3.6 million in 1H FY24, with international sales at 9.4%.

• Underlying loss improved by 20% to $8.4 million, but statutory loss widened to $15.2 million due to impairment.

• Operating cash outflow was $8 million for the half; $5 million received from R&D tax incentive and $8 million from an entitlement offer.

• Cash and equivalents at period end were $40.8 million, up from $36.3 million at 30 June 2024.

Outlook and guidance

• Focus on commercialising the EasyScreen GI Parasite Detection Kit in the US, with multiple customer sites nearing contract finalization and strong sales pipeline of over 65 prospects.

• Continued growth expected in international revenue, especially in the US and Europe, with new contracts in EMEA and ongoing evaluations in the UK and Germany.

• Strategic shift to automation and adapting commercial instruments for high-throughput, lower-cost solutions.

• Respiratory testing demand in Australia remains strong and is expected to persist.